We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need. Our initial program is gene therapy for early stage bladder cancer. Inodiftagene vixteplasmid (formerly BC-819) is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC). Inodiftagene has been tested in six clinical trials to date, three of which are in NMIBC. The pivotal development program comprises two registrational trials in NMIBC. The first of these, the Codex Trial, opened in December of 2018 and is recruiting patients now (link to ClinicalTrials.gov). We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN). Our R&D activities build upon the discovery by Professor Avraham Hochberg, of the Hebrew University of Jerusalem, of the human H19 gene. It has been shown that the gene is expressed in over forty different forms of cancer, including especially bladder cancer, while being quiescent in most normal adult tissues. H19-based therapy is designed to be a highly selective method of killing cancer cells that spares normal bladder tissue. Source
No articles found.
Life gets in the way of eating right. With a quick assessment of your lifestyle, N...
Life gets in the way of eating right. With a qu...
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated t...
electroCore, Inc. is a commercial stage bioelec...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.